Cobra BioManufacturing and Viromed Co. Extend Collaboration and Intend to Form an R&D and Commercial Supply Joint Venture
Published: Jul 24, 2008
Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has extended its manufacturing agreement and intends to form a joint venture with ViroMed Co. Ltd (South Korea), a specialist in the development of DNA and protein-based therapeutics.
The extended collaboration includes a long term research, development and technical consultancy agreement for all ViroMed products. The agreement will provide ViroMed with guaranteed process development and manufacturing resources.
Additionally, the companies have signed a memorandum of understanding to explore the potential of establishing a joint venture commercial scale biomanufacturing company that would enable the JV Company to manufacture ViroMed products for commercial supply, at the joint venture’s new facilities.
These agreements extend the manufacturing collaboration announced in June 2008, under which Cobrabio will manufacture ViroMed’s plasmid DNA therapeutic, VM206RY, for the treatment of tumours expressing Her2/neu.
Cobrabio has a long history of successful DNA projects, having been the first company to develop and gain cGMP standard DNA manufacture in Europe. Cobrabio has delivered over 30 cGMP-standard DNA manufacturing projects in the last decade, meeting consistently high levels of excellence and demonstrating an unrivalled degree of expertise.
Simon Saxby, CEO of Cobra Biomanufacturing said:
“The further development of our partnership with ViroMed is a very positive step forward for Cobrabio, providing a strong medium to long term business forecast. Having worked closely with ViroMed to develop a successful manufacturing process for its plasmid DNA product we are delighted to enter into a long term agreement, with a broad scope that will bring significant benefits to both parties.”
Dr. Sunyoung Kim, CEO of ViroMed Co., Ltd. said:
“This collaboration agreement with Cobrabio will provide quality delivery of cGMP products to ViroMed which will extend the relationship to establish a JV company.”
About Cobra Biomanufacturing Plc:
Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobrabio provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.
Cobrabio has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing business.
Cobrabio floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK. Since floatation the Company has grown turnover from $6m to $20m providing expert manufacturing services across the world with over 80% of revenues currently originating from the US market.
About ViroMed Co. Ltd:
ViroMed Co., Ltd. is an emerging Korean biotechnology company focused on the development of novel gene and protein-based therapeutics for human diseases. Its strategic focus lies in gene therapy, and, in particular, gene delivery systems such as naked DNA and retrovirus. ViroMed specializes in therapeutic areas with clear unmet medical needs: cardiovascular diseases, genetic disorders, and cancer. The company was established in 1996 and is listed on KOSDAQ, a Korean stock exchange.
For further information, please contact:
Cobra Biomanufacturing Plc Tel: +44 (0) 1782 714 181
Simon Saxby, Chief Executive Officer
Buchanan Communications Tel: +44 (0) 207 466 5000
Tim Anderson/Rebecca Skye Dietrich
College Hill Life Sciences Tel: +44 (0) 1260 296 506
Seymour Pierce (NOMAD & Broker) Tel: +44 (0) 207 107 8000